Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 14/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439235 | 0.96 | CASR (0.65) | CASRDRD2DRD4DRD3KCNH2 | |
| Hydrochloric Acid SCHEMBL5512676 | 0.94 | CASR (0.64) | CASRDRD2DRD4DRD3KCNH2 | |
| SCHEMBL5521284 | 0.92 | CASR (0.64) | CASRDRD2DRD4DRD3KCNH2 | |
| SCHEMBL14522208 | 0.83 | CASR (0.68) | CASRDRD2DRD4DRD3KCNH2 | |
| SCHEMBL5527612 | 0.82 | CASR (0.59) | CASRALDH1A1MEN1KMT2A | |
| SCHEMBL14383034 | 0.80 | CASR (0.74) | CASRKCNH2ADRB2ADRB3CYP2D6 | |
| SCHEMBL14382945 | 0.80 | CASR (1.00) | CASRKCNH2ADRB2ADRB3CYP2D6 | |
| SCHEMBL14382943 | 0.80 | CASR (1.00) | CASRKCNH2ADRB2ADRB3CYP2D6 | |
| SCHEMBL14382947 | 0.80 | CASR (1.00) | CASRKCNH2ADRB2ADRB3CYP2D6 | |
| SCHEMBL5519885 | 0.80 | CASR (0.56) | CASRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0901459-B1 | CALCILYTIC COMPOUNDS | NPS PHARMA INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050032850-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| US-6818660-B2 | FOR INHIBITING CALCIUM RECEPTOR ACTIVIT; TO STIMULATE SECRETION OF PARATHYROID HORMONE (PTH); FOR BONE FORMATION | NPS PHARMACEUTICALS, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6432656-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020099220-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6022894-A | Method of using calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032850-A1 | Calcilytic compounds | CALCR, CASR, ORAI1 | CASR 2/4885DRD2 2114/4885DRD4 3589/4885 |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | CALCR, CASR, ORAI1 | CASR 2/4885DRD2 2114/4885DRD4 3589/4885 |
| US-20020099220-A1 | Calcilytic compounds | CALCR, CASR, CALCRL | CASR 2/4885DRD2 2398/4885DRD4 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.